Barclays’s CRISPR Therapeutics CRSP Stock Holding History

Barclays’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,000	Closed	-$1.19M	–	5396
2026 Q1	$1.19M	Buy	+25,000	New	+$1.32M	﹤0.01%	2652
2024 Q4	–	Sell	-30,000	Closed	-$1.41M	–	5307
2024 Q3	$1.41M	Sell	30,000 -84,000	-74%	-$4.26M	﹤0.01%	3127
2024 Q2	$6.16M	Buy	114,000 +87,000	+322%	+$5.03M	﹤0.01%	1425
2024 Q1	$1.84M	Sell	27,000 -25,000	-48%	-$1.79M	﹤0.01%	2640
2023 Q4	$3.26M	Buy	+52,000	New	+$2.87M	﹤0.01%	2491
2021 Q1	–	Sell	-2,500	Closed	-$383K	–	4767
2020 Q4	$383K	Buy	+2,500	New	+$295K	﹤0.01%	3401
2018 Q2	–	Sell	-34,700	Closed	-$1.59M	–	7007
2018 Q1	$1.59M	Buy	+34,700	New	+$1.43M	﹤0.01%	2715

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Barclays's CRSP Position: Q2 2026 in Review

Barclays increased its CRISPR Therapeutics (CRSP) stake by 27% in Q2 2026, buying an estimated $455K and bringing the position to 40,879 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2284.

Barclays first reported a position in CRSP in Q3 2017 and has held it in 36 quarters since. The position peaked at $23.2M in Q3 2023. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Barclays held 40,879 shares of CRISPR Therapeutics worth $2.23M as of Q2 2026.
Barclays bought 8,625 CRISPR Therapeutics shares in Q2 2026, an estimated $455K.
CRISPR Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2284 holding.
Barclays first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 36 quarters since.
Barclays's CRISPR Therapeutics position peaked at $23.2M in Q3 2023.
523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.